In 2024, the business plans to partner with Novartis’ Sandoz to co-produce and market Humira biosimilar Hyrimoz (adalimumab-adaz) for more than 80 percent less than the biologic’s price, which is nearly $7,000 a month.
“The Cordavis products will be FDA approved, high quality and easy for patients to use and will help ensure consistent long-term supply of affordable biosimilars,” CVS said in a statement.
The Cordavis launch coincides with a workforce restructuring of about 2 percent of its total workforce. CVS is cutting 5,000 jobs and has filed WARN notices for laying off 2,705 workers across nine states.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
